title: High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
abstract: We describe the results of 37 myeloma patients who received bortezomib following reduced intensity allogeneic stem cell transplantation (RIC-allo-SCT). Grade 1-2 peripheral neuropathy (35%), mild thrombocytopenia (24%) and fatigue (19%) were the most frequent adverse events, while there was no worsening of graft-vs-host disease symptoms. Twenty-seven patients (73%; 95% CI, 59-87%) achieved an objective response. With a median follow-up of 9 months from bortezomib initiation, the estimate of overall survival was 65% at 18 months while this was significantly higher (p=0.002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.
authors.affiliation: Unité de Transplantation et de Thérapie Cellulaire (UTTC), Institut Paoli-Calmettes, Marseille, France.
authors.forename: Jean
authors.initials: J
authors.lastname: El-Cheikh
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Arnon
authors.initials: A
authors.lastname: Nagler
authors.forename: Hugues
authors.initials: H
authors.lastname: de Lavallade
authors.forename: Franck E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: Avichai
authors.initials: A
authors.lastname: Shimoni
authors.forename: Catherine
authors.initials: C
authors.lastname: Faucher
authors.forename: Mohamad
authors.initials: M
authors.lastname: Sobh
authors.forename: Daniela
authors.initials: D
authors.lastname: Revesz
authors.forename: Izhar
authors.initials: I
authors.lastname: Hardan
authors.forename: Sabine
authors.initials: S
authors.lastname: Fürst
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D005221:Fatigue / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D010523:Peripheral Nervous System Diseases / Q000209:etiology; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000209:etiology; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib